Clinical Trial Update: Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Tadekinig alfa for adult-onset Still's disease has completed, providing updated results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adult-onset Still Disease

Drugs mentioned

• Tadekinig Alfa (tadekinig alfa)

Snippet

Sponsor: AB2 Bio Ltd. | Conditions: Still's Disease, Adult-Onset | Phase 2 | Status: COMPLETED